Bianchini Diletta, Jayanth Akali, Chua Yu Jo, Cunningham David
Department of Medicine, Royal Marsden Hospital, Down's Road, Sutton, Surrey, SM2 5PT UK.
Clin Colorectal Cancer. 2008 Jan;7(1):33-43. doi: 10.3816/CCC.2008.n.005.
The human epidermal growth factor receptor (HER1/EGFR/ErbB1) signaling is aberrant and overexpressed in many solid malignancies making it an appealing target for biologic agents. Among the classes of drugs targeting EGFR are monoclonal antibodies and EGFR tyrosine kinase inhibitors, which have been shown effective and generally well tolerated in different clinical settings. The majority of patients treated with EGFR inhibitors (EGFRIs) develop specific dose-dependent skin toxicity. This side effect may lead to physical and psychosocial discomfort which can result in dose reduction or treatment interruption. The relationship between rash and clinical outcome has stimulated interest in this particular toxicity as a possible surrogate marker of efficacy in patients treated with targeted agents against EGFR. This review aims to summarize and update the current knowledge of the clinical presentation, predictive and prognostic value, and the management of EGFRI-related skin toxicity.
人表皮生长因子受体（HER1/EGFR/ErbB1）信号传导在许多实体恶性肿瘤中异常且过度表达，这使其成为生物制剂的一个有吸引力的靶点。靶向表皮生长因子受体（EGFR）的药物类别包括单克隆抗体和EGFR酪氨酸激酶抑制剂，这些药物在不同临床环境中已显示出有效性且总体耐受性良好。大多数接受EGFR抑制剂（EGFRIs）治疗的患者会出现特定的剂量依赖性皮肤毒性。这种副作用可能导致身体和心理社会不适，进而可能导致剂量减少或治疗中断。皮疹与临床结局之间的关系激发了人们对这种特殊毒性的兴趣，将其作为接受EGFR靶向药物治疗患者疗效的一种可能替代标志物。本综述旨在总结和更新关于EGFRIs相关皮肤毒性的临床表现、预测和预后价值以及管理的当前知识。
